Hirsch Andrew 4
4 · C4 Therapeutics, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
C4 Therapeutics CEO Andrew Hirsch Receives 700K RSU Award
What Happened
Andrew Hirsch, President & CEO and a director of C4 Therapeutics (CCCC), was granted 700,000 restricted stock units (RSUs) on Feb 13, 2026. In addition, previously awarded RSUs vested and converted into 102,125 shares on Feb 14–15, 2026 (reported as "M" — exercise/conversion of derivative, $0 cost). To satisfy tax withholding obligations, 48,211 of those shares were withheld (reported as "F") at $1.89 per share for cash value of $74,001 (39,154 shares) on Feb 14 and $17,118 (9,057 shares) on Feb 15. Net share increase from these vest/settlements: 53,914 shares.
Key Details
- Grant: 700,000 RSUs granted 2026-02-13 (reported as "A"), acquisition price $0.
- Vesting conversions: 81,725 shares acquired 2026-02-14 and 20,400 shares acquired 2026-02-15 (both "M", $0).
- Tax withholding: 39,154 shares withheld 2/14 for $74,001 and 9,057 shares withheld 2/15 for $17,118 (both "F"); total withheld value $91,119. These withholdings are not open-market sales by Hirsch.
- Shares owned after transaction: Not specified in the filing.
- Footnotes: F1 explains the 700K RSU vesting schedule (350,000 vest in three equal annual installments beginning Feb 13, 2027; remaining 350,000 vest in full on Feb 13, 2029, subject to performance acceleration). F2 notes the converted shares came from previously disclosed RSU grants (reported in prior Forms 4). F3 clarifies withheld shares satisfy tax obligations and are not a sale.
- Filing: Form filed 2026-02-18 reporting transactions dated Feb 13–15, 2026. Form 4s are typically due within two business days of a transaction; the filing date is shown as Feb 18.
Context
- "M" transactions here reflect conversion/vesting of RSUs or other derivatives into common stock; the conversions recorded $0 acquisition price because the shares resulted from vested RSUs.
- "F" entries represent shares withheld by the company to cover taxes, not an open-market sale — common practice on RSU settlements.
- This filing reports award and routine vesting/withholding activity; it is factual disclosure and does not by itself indicate insider sentiment about the stock.
Insider Transaction Report
Form 4
Hirsch Andrew
DirectorPresident & CEO
Transactions
- Award
Common Stock
[F1]2026-02-13+700,000→ 1,123,145 total - Exercise/Conversion
Common Stock
[F2]2026-02-14+81,725→ 1,123,145 total - Tax Payment
Common Stock
[F3]2026-02-14$1.89/sh−39,154$74,001→ 1,083,991 total - Exercise/Conversion
Common Stock
[F2]2026-02-15+20,400→ 1,083,991 total - Tax Payment
Common Stock
[F3]2026-02-15$1.89/sh−9,057$17,118→ 1,074,934 total
Footnotes (3)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 350,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 350,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
- [F2]Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025.
- [F3]Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Signature
/s/ Shagha Russell, Attorney-in-Fact|2026-02-18